Clinical Services & Novel Diagnostic Test Development
FYR Diagnostics harnesses the disease-relevant cargo of Extracellular Vesicles (EVs) to develop the next generation of liquid biopsy biomarkers for critical disease areas in human health that have unmet diagnostic needs. What are EVs? EVs are membrane enclosed nanoparticles that contain molecular cargo (e.g., RNA, protein) released by cells, tissues, and organs in the body. EV-biomarkers can be non-invasively accessed through liquid biopsies (e.g. blood draw, urine sample) and contain relevant molecular information that not only highly correlates with disease status but also with relevant clinical outcomes.
FYR is focused on several operational areas to help develop and transition these diagnostics from the bench to the bedside. These include novel biomarker discovery, assay development, high-throughput molecular testing, and innovative analytics. Additionally, FYR offers clinical services through its CLIA lab and assay development pipeline to facilitate clinical studies, clinical trials, data generation and analysis, and diagnostic test development and deployment.